Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2004-02-10
2010-02-02
O'Sullivan, Peter G (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S443000, C548S467000, C549S051000, C549S052000, C549S054000, C549S055000
Reexamination Certificate
active
07655641
ABSTRACT:
The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 6248781 (2001-06-01), Jeppesen et al.
patent: 6306854 (2001-10-01), Brown et al.
patent: 6369098 (2002-04-01), Pershadsingh et al.
patent: 6506757 (2003-01-01), Tajima et al.
patent: 6518290 (2003-02-01), Sierra
patent: 7071220 (2006-07-01), Satoh et al.
patent: 0 930 229 (1999-07-01), None
patent: 1 167 357 (2002-02-01), None
patent: 1 216 980 (2002-06-01), None
patent: 2 359 082 (2001-08-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/31907 (1997-09-01), None
patent: WO 01/00566 (2001-01-01), None
patent: WO 01/16120 (2001-03-01), None
patent: WO 02/16332 (2002-02-01), None
patent: WO 02/18355 (2002-03-01), None
patent: WO 02/100813 (2002-12-01), None
patent: WO 03/072099 (2003-09-01), None
Sato, et al., “Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists,”Eur. J. Med. Chem., 30, pp. 403-414 (1995).
Sato, et al., “Asymmetric Synthesis of the Sulfoxide Metabolite of On-579 By The Kagan Protocol,”Bioorganic and Medicinal Chemistry Letters, vol. 7 No. 19, pp. 2451-2454 (1997).
Shinozaki, et al., “Synthesis and thromboxane A2 antagonist activity of indane derivatives,”Bioorganic and Medicinal Chemistry Letters, vol. 9, pp. 401-406 (1999).
Sato, et al., “Synthesis and evaluation of novel sulfonamide derivatives as thromboxane A2 receptor antagonists I,”Eur. J. Med. Chem., vol. 29, pp. 185-190 (1994).
Berlot, et al., “Preparation of a dansylated fibrate, a new fluorescent tool to study peroxisome proliferation. Effect on hepatic-derived cell lines,”Biochimie, vol. 79, pp. 145-150 (1997).
Liu, et al., “Identification of a Series of PPARγ/δ Dual Agonists Via Solid-Phase Parallel Synthesis,”Bioorganic and Medicinal Chemistry Letters, vol. 11, pp. 2959-2962 (2001).
Sarges, et al., “Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-phenoxy-3-phenylpropanoic Acids,” J. Med. Chem., vol. 39, No. 24, pp. 4783-4802 (Nov. 22, 1996).
Cobb, et al., “N-(2-Benzoylphenyl)-L-tyrosine PPAR Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,” J. Med. Chem., vol. 41, No. 25, pp. 5055-5069 (Dec. 3, 1998).
Bright, et al., “Competitive particle concentration fluorescence immunoassays for measuring anti-diabetic drug levels in mouse plasma,” Journal of Immunological Methods, vol. 207, No. 1, pp. 23-31 (Aug. 2, 1997).
Brooks, et al., “Design and Synehesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic Acids: A New Class of Dual PPAR Agonists,” J. Med. Chem., vol. 44, No. 13, pp. 2061-2064 (Jun. 21, 2001).
Shinkai, et al., “Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents,” J. Med. Chem., vol. 41, No. 11, pp. 1927-1933 (May 21, 1998).
Murugesan, et al., “Biphenylsulfonamide Endohelin Receptor Antagonists. 2. Discovery of 4′-Oxazolyl biphenylsulfonamides as a New Class of Potent, Highly Selective ETAAntagonists,” J. Med. Chem., vol. 43, No. 16, pp. 3111-3117 (Aug. 10, 2000).
Malamas, et al., “Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase,” J. Med. Chem., vol. 39, No. 1, pp. 237-245 (Jan. 5, 1996).
Meguro, et al., “Studies on Antidiabetic Agents. VIII. Synthesis and Hypoglycemic Activity of 4-Oxazoleacetic Acid Derivatives,” Chemical & Pharmaceutical Bulletin, vol. 34, No. 7, pp. 2840-2851 (1986).
Xu, Yanping, et al., “Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists,” J. Med. Chem, vol. 47, No. 10, pp. 2422-2425 (2004).
Conner Scott Eugene
Gossett Lynn Stacy
Green Jonathan Edward
Jones, Jr. Winton Dennis
Mantlo Nathan Bryan
Eli Lilly and Company
O'Sullivan Peter G
Vorndran-Jones MaCharri
LandOfFree
Sulfonamide derivatives as PPAR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamide derivatives as PPAR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide derivatives as PPAR modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172462